NCT02566655已完成1 期
Phase I Clinical Trial To Evaluate The Intravenous Infusion Of Autologous Fucosylated Bone Marrow Mesenchymal Cells Therapy In Patients With Established Osteoporosis and Low Impact Fractures
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 10
- 试验地点
- 2
- 主要终点
- Rate of serious and non-serious adverse events related to the procedure.
研究概览
简要总结
The purpose of this study is to evaluate the safety of intravenous infusion of fucosylated autologous bone marrow cells as a new therapy in patients with established osteoporosis by a prospective, single-center, open, non-randomized and unblinded clinical trial.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 50 Years 至 70 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patients with established osteoporosis according to standard clinical criteria.
- •Patients who give their written informed consent to participate in the study consent.
- •Meet all the inclusion criteria
排除标准
- •Patients with concomitant systemic disease in the opinion of the investigator.
- •Patients with rheumatoid arthritis, ankylosing spondylitis, chronic polyarticular arthritis.
- •Current patients with neoplasm or history of any malignancy in the last 10 years except basal carcinoma or epidermoid skin.
- •Patients with genetic disorders that are associated with secondary osteoporosis: Hemochromatosis, hypophosphatasia, osteogenesis imperfecta, Ehlers-Danlos syndrome, Marfan syndrome, Riley Day, porphyria, storage diseases syndrome.
- •Patients receiving immunosuppressive chemotherapy or that could interfere with the process of cell proliferation.
- •Transplant patients: bone marrow, kidney, liver, heart, lung.
- •Patients with clinical criteria and anesthetics that contraindicate well sedation or bone marrow extraction.
- •Patients participating in a clinical trial in the last 6 months.
- •Patients with positive serology for hepatitis B, hepatitis C or HIV.
- •Patients with inability to understand informed consent.
- •Patients who are pregnant or breast-feeding actively.
- •Patients physically fertile, defined as all women physiologically capable of becoming pregnant, UNLESS they are using reliable methods of contraception.
结局指标
主要结局
Rate of serious and non-serious adverse events related to the procedure.
时间窗: 24 months from baseline
During time frame the following items will be considered: Adverse effects related to the infusion moment. Occurrence of infectious complications after infusion of mesenchymal stem cells, because of the immunosuppressive effect of these cells. Appearance of procedure-related neoplasias.
次要结局
- Pain, measured by Visual Analog Scale(24 months from baseline)
- Quality of Life, measured by EuroQoL-5D test(24 months from baseline)
- Bone resorption, measured by biochemical index(24 months from baseline)
- Bone structure, measured by histomorphometric evaluation(baseline and 4 months from baseline)
- Number of new fractures(24 months from baseline)
- Trabecular bone density measured by quantitative computed tomography of the radius(24 months from baseline)
- Bone Mineral Density , measured by dual energy x-ray absorptiometry (DXA)(24 months from baseline)
- Functionality, measured by Oswestry Disability Questionnaire(24 months from baseline)
- Bone metabolism, measured by biochemical index(24 months from baseline)
- Bone formation, measured by biochemical index(24 months from baseline)
研究者
研究点 (2)
Loading locations...
相似试验
招募中
1 期
Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian CancerOvarian CancerNCT05316129H. Lee Moffitt Cancer Center and Research Institute10
招募中
3 期
A Study to Investigate the Safety and Efficacy of Undiluted Intravenous Infusion of I.V.-Hepabig Inj.Hepatitis BNCT05686759GC Biopharma Corp105
已完成
1 期
Safety and Pharmacokinetic Study of EO9(Intravesical Instillation)Bladder CancerNCT01373398Handok Inc.11
招募中
1 期
Phase 1 Hepatic Insufficiency Trial of Methoxyethyl Etomidate HydrochlorideHepatic InsufficiencyNCT06176716Ahon Pharmaceutical Co., Ltd.24
终止
1 期
Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous LeukemiaAdvanced MDSALLAdvanced CMLAdvanced MPNsAMLNCT02795520OncoTherapy Science, Inc.32